Current and historical daily PE Ratio for Yumanity Therapeutics Inc (
FRA:8IY
) from 2020 to May 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Yumanity Therapeutics stock (FRA:8IY) PE ratio as of May 22 2024 is 0.
More Details
Yumanity Therapeutics Inc (FRA:8IY) PE Ratio (TTM) Chart
Yumanity Therapeutics Inc (FRA:8IY) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 565
- 1
- 2
- 3
- 4
- 5
- 6
- 7
| Yumanity Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-22 | At Loss | 2022-10-14 | At Loss |
| 2022-12-16 | At Loss | 2022-10-13 | At Loss |
| 2022-12-15 | At Loss | 2022-10-12 | At Loss |
| 2022-12-14 | At Loss | 2022-10-11 | At Loss |
| 2022-12-13 | At Loss | 2022-10-10 | At Loss |
| 2022-12-12 | At Loss | 2022-10-07 | At Loss |
| 2022-12-09 | At Loss | 2022-10-06 | At Loss |
| 2022-12-08 | At Loss | 2022-10-05 | At Loss |
| 2022-12-07 | At Loss | 2022-10-04 | At Loss |
| 2022-12-06 | At Loss | 2022-10-03 | At Loss |
| 2022-12-05 | At Loss | 2022-09-29 | At Loss |
| 2022-12-02 | At Loss | 2022-09-28 | At Loss |
| 2022-12-01 | At Loss | 2022-09-27 | At Loss |
| 2022-11-30 | At Loss | 2022-09-26 | At Loss |
| 2022-11-29 | At Loss | 2022-09-23 | At Loss |
| 2022-11-28 | At Loss | 2022-09-22 | At Loss |
| 2022-11-25 | At Loss | 2022-09-21 | At Loss |
| 2022-11-24 | At Loss | 2022-09-20 | At Loss |
| 2022-11-23 | At Loss | 2022-09-19 | At Loss |
| 2022-11-22 | At Loss | 2022-09-16 | At Loss |
| 2022-11-21 | At Loss | 2022-09-15 | At Loss |
| 2022-11-18 | At Loss | 2022-09-14 | At Loss |
| 2022-11-17 | At Loss | 2022-09-13 | At Loss |
| 2022-11-16 | At Loss | 2022-09-12 | At Loss |
| 2022-11-15 | At Loss | 2022-09-09 | At Loss |
| 2022-11-14 | At Loss | 2022-09-08 | At Loss |
| 2022-11-11 | At Loss | 2022-09-07 | At Loss |
| 2022-11-10 | At Loss | 2022-09-06 | At Loss |
| 2022-11-09 | At Loss | 2022-09-05 | At Loss |
| 2022-11-08 | At Loss | 2022-09-02 | At Loss |
| 2022-11-07 | At Loss | 2022-09-01 | At Loss |
| 2022-11-04 | At Loss | 2022-08-30 | At Loss |
| 2022-11-03 | At Loss | 2022-08-29 | At Loss |
| 2022-11-02 | At Loss | 2022-08-26 | At Loss |
| 2022-11-01 | At Loss | 2022-08-25 | At Loss |
| 2022-10-28 | At Loss | 2022-08-24 | At Loss |
| 2022-10-27 | At Loss | 2022-08-23 | At Loss |
| 2022-10-26 | At Loss | 2022-08-22 | At Loss |
| 2022-10-25 | At Loss | 2022-08-19 | At Loss |
| 2022-10-24 | At Loss | 2022-08-18 | At Loss |
| 2022-10-21 | At Loss | 2022-08-17 | At Loss |
| 2022-10-20 | At Loss | 2022-08-16 | At Loss |
| 2022-10-19 | At Loss | 2022-08-15 | At Loss |
| 2022-10-18 | At Loss | 2022-08-12 | At Loss |
| 2022-10-17 | At Loss | 2022-08-11 | At Loss |
Yumanity Therapeutics Inc (FRA:8IY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Yumanity Therapeutics Inc
NAICS : 325412
SIC : 2834
Share Class Description:
FRA:8IY: Ordinary SharesCompare
Compare
Traded in other countries / regions
8IY.Germany IPO Date
2020-12-23Description
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers